Hematologic responses and leukemic blasts in BM and PB prior to start of imatinib
Response . | N = 21 . | BM blast infiltration prior to start of imatinib as evaluated by BM cytology, % . | Maximal absolute PB blast count prior to start of imatinib, per μL . |
|---|---|---|---|
| Complete hematologic response (CHR) | 2 (PNs 4, 7) | PN 4: 5-10; PN 7: 2 | PN 4: 144; PN 7: 384 |
| No leukemic evidence (NLE) | 1 (PNs 9) | PN 9: 5 | PN 9: 1808 |
| Minor response (MR) | 2 (PNs 5, 18) | PN 5: 13 | PN 5: 1080 |
| PN 18: 62 | PN 18: 686 | ||
| Total (%) | 5 (24) | — | — |
Response . | N = 21 . | BM blast infiltration prior to start of imatinib as evaluated by BM cytology, % . | Maximal absolute PB blast count prior to start of imatinib, per μL . |
|---|---|---|---|
| Complete hematologic response (CHR) | 2 (PNs 4, 7) | PN 4: 5-10; PN 7: 2 | PN 4: 144; PN 7: 384 |
| No leukemic evidence (NLE) | 1 (PNs 9) | PN 9: 5 | PN 9: 1808 |
| Minor response (MR) | 2 (PNs 5, 18) | PN 5: 13 | PN 5: 1080 |
| PN 18: 62 | PN 18: 686 | ||
| Total (%) | 5 (24) | — | — |
PN indicates patient number; — indicates no total.